Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPERION
2023-505990-34-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in aggressive B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and 8 more, sponsored by Karolinska University Hospital. Primary endpoints: Event-free survival at 3 years, Event-free survival and 8 more. Planned start Mar 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
aggressive B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)large-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-505990-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505990-34-00.